Form 4: Director Michael Holder Increases Stake in Cytek Biosciences

Director Michael Holder acquired 43,973 shares of Cytek Biosciences through RSU vesting while receiving new equity grants.

Summary

• Director Michael Holder exercised 43,973 Restricted Stock Units (RSUs) on June 10, 2026, resulting in the acquisition of 43,973 shares of common stock.
• Following the transaction, the director holds a total of 60,694 shares of common stock.
• The director was granted 33,333 new RSUs and 18,261 stock options with an exercise price of $4.05.
• The new equity grants are scheduled to vest on the earlier of June 10, 2027, or the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard director compensation and equity vesting rather than a strategic shift or market-moving event.

Positives

• Director maintains a direct ownership stake in the company, aligning interests with shareholders.
• The acquisition of shares through RSU vesting indicates ongoing compensation and retention of board leadership.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Future vesting of equity grants is contingent upon the director's continued service and the timing of the 2027 annual meeting.

Future Outlook

The director's new equity grants are set to vest in June 2027, contingent upon continued service and the timing of the 2027 annual meeting.

Management Comments

• No narrative comments provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation and equity alignment, which is standard practice for publicly traded life sciences companies like Cytek Biosciences.

Comparison to Industry Standards

• The equity grant structure is consistent with standard corporate governance practices for NASDAQ-listed biotechnology firms.
• Vesting schedules tied to annual meetings are common among peer companies in the life sciences sector.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive sign of confidence in the company's long-term prospects.

Next Steps

• Vesting of new RSU and option grants on June 10, 2027.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Trading, Director Compensation, Equity Grants